|
Nectar Lifescience Ltd share price declined by 4.94% to Rs 10.78 after the company's net profit tumbled by 77.33% to Rs 15.4 crore, while revenue from operations remained flat to Rs 0.01 crore in Q2FY26 over Q1FY26.
The market capitalization of Pharmaceuticals industry group stocks on BSE stood at Rs 26.82 lakh crore, rising 4.11%. It has slipped by 1.63% over last one week and softened by 0.99% in last one month while the market capitalization of Nectar Lifescience Ltd has marginally improved by 7.26% and 4.66% in the same period respectively.
Profit before tax (PBT) of Nectar Lifescience Ltd stood at Rs 24.3 crore in Q2 FY26, crashing by 61.79% year-on-year, and plunging by 72.27% quarter-on-quarter. EBITDA came in at Rs 30 crore, expanding by 2502.59% YoY and tumbling by 52.48% sequentially.
Total expenses plunged by 52.53% to Rs 27.82 crore in Q2FY26 over Q2FY25. During the quarter, employee benefits expense was at Rs 1.06 crore, tanking by 15.87% YoY.
For the TTM ended FY26, revenue from operations sank 100% , while net profit witnessed a sharp fall of 8292.86% to Rs 57.35 crore, compared to previous TTM. EBITDA saw a sharp decline of 329% to Rs 65.97 crore, and PBT collapsed by 8313.08% to Rs 87.88 crore compared to previous TTM.
The company's consolidated net cash flow from operating activities stood at Rs 348.72 crore in FY26, as against Rs 169.44 crore in FY25.
Nectar Lifescience Ltd crashed 14.80% in last one year, significantly underperforming the benchmark BSE Sensex which has reduced by 12.69% during the same period.
|